Type 2 & other diabetes

Novel OGTT metrics do not provide incremental predictive value beyond conventional glycemic criteria for remission of prediabetes in individuals with impaired fasting glucose: results from the PREVIEW trial

Cardiovasc DiabetolPublished Secondary analysis of the PREVIEW randomised trial

Authors' conclusion

In long-term lifestyle intervention among individuals who predominantly had IFG, individual novel OGTT metrics do not provide incremental predictive value for prediabetes remission beyond conventional metrics of glycemia.

Study context

Population
Adults with overweight/obesity and predominantly impaired fasting glucose (IFG) in a lifestyle intervention trial (8-week weight loss, then 148-week weight maintenance)
Participants
1,187 adults
Comparison
Novel OGTT metrics vs conventional glycaemic metrics for predicting prediabetes remission
  • Remittersn = 262
  • Non-remittersn = 925reference
Primary endpoint
Prediabetes remission
Follow-up
1, 2, and 3 years
Methodological detailspost-hoc analysis, multinational, 3-year
  • Post-hoc analysis
  • Multinational
  • 3-year

Primary result

As reported in the abstract

Incremental predictive value of novel OGTT metrics for prediabetes remission beyond conventional metrics
Adding individual novel OGTT metrics did not significantly improve model fit or discrimination (likelihood ratio tests, ΔAUROC, net reclassification improvement (NRI))
P > 0.05

Further findings

Baseline fasting glucose and prediabetes remission · 1 year

Non-linear association at 1 year
P = 0.008
Inverse linear associations at 2 and 3 years, independent of 2-h glucose and HbA1c

Baseline HbA1c and 2-h glucose and prediabetes remission · 1, 2, and 3 years

Higher baseline HbA1c, but not 2-h glucose, associated with lower likelihood of remission, regardless of fasting and 2-h glucose

Original publication

Novel OGTT metrics do not provide incremental predictive value beyond conventional glycemic criteria for remission of prediabetes in individuals with impaired fasting glucose: results from the PREVIEW trial. Cardiovasc Diabetol. Published 22 April 2026. doi:10.1186/s12933-026-03186-0

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.